VIP (Vasoactive Intestinal Peptide)
28-amino-acid vasoactive and immunomodulatory neuropeptide (secretin/glucagon family)
Vasoactive intestinal peptide (VIP) is a 28-amino-acid neuropeptide with broad roles in vasodilation, smooth-muscle relaxation, secretion, and immune regulation. A synthetic form, aviptadil, has been investigated clinically for respiratory and pulmonary conditions. Some research communities use intranasal VIP; the systemic half-life is very short.
Mechanism under study
Signals through VPAC1 and VPAC2 G-protein-coupled receptors, raising cyclic AMP to produce vasodilation, bronchodilation, gut smooth-muscle relaxation, and anti-inflammatory/immunomodulatory effects. Studied across pulmonary, gastrointestinal, and immune contexts.
Research-reported dosing
Contexts differ: clinical aviptadil has been studied as a controlled IV infusion (microgram-level dosing), while research-community intranasal VIP protocols cite roughly 50 mcg per spray several times daily. Aviptadil is investigational; VIP is not an approved general-use drug.
Research VIP is commonly prepared as an intranasal solution rather than a subcutaneous injection. If a lyophilized vial is reconstituted, 5 mg + 2 mL bacteriostatic water = 2,500 mcg/mL (2.5 mg/mL); intranasal microgram dosing means only a fraction of a mL is used per administration.
A 50 mcg dose ≈ 2 units (25 mcg per unit).
Open this mix in the calculator →Dosing figures describe how this compound appears in the research literature and research-community references. They are not a recommendation for human use.
VIP (Vasoactive Intestinal Peptide) FAQ
What is VIP (Vasoactive Intestinal Peptide)?
Vasoactive intestinal peptide (VIP) is a 28-amino-acid neuropeptide with broad roles in vasodilation, smooth-muscle relaxation, secretion, and immune regulation. A synthetic form, aviptadil, has been investigated clinically for respiratory and pulmonary conditions. Some research communities use intranasal VIP; the systemic half-life is very short.
What is the half-life of VIP (Vasoactive Intestinal Peptide)?
Very short - roughly 1-2 minutes in plasma - which is why clinical aviptadil is given by infusion and why intranasal routes are explored.
What is the research-reported dosing for VIP (Vasoactive Intestinal Peptide)?
Contexts differ: clinical aviptadil has been studied as a controlled IV infusion (microgram-level dosing), while research-community intranasal VIP protocols cite roughly 50 mcg per spray several times daily. Aviptadil is investigational; VIP is not an approved general-use drug.
How is VIP (Vasoactive Intestinal Peptide) reconstituted?
Research VIP is commonly prepared as an intranasal solution rather than a subcutaneous injection. If a lyophilized vial is reconstituted, 5 mg + 2 mL bacteriostatic water = 2,500 mcg/mL (2.5 mg/mL); intranasal microgram dosing means only a fraction of a mL is used per administration.
Is VIP (Vasoactive Intestinal Peptide) FDA-approved?
No — VIP (Vasoactive Intestinal Peptide) is investigational and not FDA-approved. It is sold for laboratory research use only.
References
Related peptides
BPC-157
Synthetic pentadecapeptide
A stable synthetic peptide based on a partial sequence identified in gastric juice. It is one of the most-studied research peptides for connective-tissue and gut-lining repair in animal models.
KPV
Alpha-MSH-derived tripeptide
A tripeptide fragment (Lys-Pro-Val) derived from the C-terminus of alpha-MSH, studied for anti-inflammatory effects, particularly in models of gut inflammation.
LL-37
Cathelicidin-derived antimicrobial peptide
The only human cathelicidin antimicrobial peptide, studied for direct antimicrobial activity as well as roles in inflammation and wound healing. Human therapeutic use is investigational.
Thymosin Alpha-1
Immunomodulatory 28-amino-acid peptide
An immune-modulating 28-amino-acid peptide, marketed as Zadaxin in a number of countries. It is among the more clinically studied immune peptides, though it is not FDA-approved in the United States.